GWGuihai Wu

Guihai Wu

*This is an algorithmically generated author record based on publicly available information.

Guihai Wu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Xuerui Tan

    Department of Cardiology, the First Affiliated Hospital of Shantou University Medical College, Shantou, China

    2 shared publications
  • Gang Yin

    Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), Cardiology, Shantou, China

    1 shared publication
  • Jing-Yi Yan

    Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    1 shared publication
  • Jinxiu Zhu

    Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), Cardiology, Shantou, China

    1 shared publication
  • Jinxiu Zhu

    Institute of Clinical Electrocardiology, the First Affiliated Hospital of Shantou University Medical College, Shantou, China

    1 shared publication
  • Nan Lu

    Department of Cardiology, the First Affiliated Hospital of Shantou University Medical College, Shantou, China

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    6‐Gingerol Alleviates Ferroptosis and Inflammation of Diabetic Cardiomyopathy via the Nrf2/HO‐1 Pathway

    by Shenglin Wu, Jinxiu Zhu, Guihai Wu, Zuoqi Hu, Pengxiang Ying, Zhijun Bao, Zipeng Ding, Xuerui Tan

    Background. Diabetes mellitus (DM) can induce cardiomyocyte injury and lead to diabetic cardiomyopathy (DCM) which presently has no specific treatments and consequently increase risk of mortality. Objective. To characterize the therapeutic effect of 6‐gingerol (6‐G) on DCM and identify its potential mechanism. Methods. In vivo streptozotocin‐ (STZ‐) induced DM model was established by using a high‐fat diet and STZ, followed by low‐dose (25 mg/kg) and high‐dose (75 mg/kg) 6‐G intervention. For an in vitro DCM model, H9c2 rat cardiomyoblast cells were stimulated with high glucose (glucose = 33 mM) and palmitic acid (100 μM) and then treated with 6‐G (100 μM). Histological and echocardiographic analyses were used to assess the effect of 6‐G on cardiac structure and function in DCM. Western blotting, ELISA, and real‐time qPCR were used to assess the expression of ferroptosis, inflammation, and the Nrf2/HO‐1 pathway‐related proteins and RNAs. Protein expression of collagen I and collagen III was assessed by immunohistochemistry, and kits were used to assay SOD, MDA, and iron levels. Results. The results showed that 6‐G decreased cardiac injury in both mouse and cell models of DCM. The cardiomyocyte hypertrophy and interstitial fibrosis were attenuated by 6‐G treatment in vivo and resulted in an improved heart function. 6‐G inhibited the expression of ferroptosis‐related protein FACL4 and the content of iron and enhanced the expression of anti‐ferroptosis‐related protein GPX4. In addition, 6‐G also diminished the secretion of inflammatory cytokines, including IL‐1β, IL‐6, and TNF‐α. 6‐G treatment activated the Nrf2/HO‐1 pathway, enhanced antioxidative stress capacity proved by increased activity of SOD, and decreased MDA production. Compared with in vivo, 6‐G treatment of H9c2 cells treated with high glucose and palmitic acid could produce a similar effect. Conclusion. These findings suggest that 6‐G could protect against DCM by the mechanism of ferroptosis inhibition and inflammation reduction via enhancing the Nrf2/HO‐1 pathway.


  • Open Access

    Development and Validation of a Nomogram to Predict the 180-Day Readmission Risk for Chronic Heart Failure: A Multicenter Prospective Study

    by Shanshan Gao, Gang Yin, Qing Xia, Guihai Wu, Jinxiu Zhu, Nan Lu, Jingyi Yan, Xuerui Tan

    Background: The existing prediction models lack the generalized applicability for chronic heart failure (CHF) readmission. We aimed to develop and validate a widely applicable nomogram for the prediction of 180-day readmission to the patients.Methods: We prospectively enrolled 2,980 consecutive patients with CHF from two hospitals. A nomogram was created to predict 180-day readmission based on the selected variables. The patients were divided into three datasets for development, internal validation, and external validation (mean age: 74.2 ± 14.1, 73.8 ± 14.2, and 71.0 ± 11.7 years, respectively; sex: 50.2, 48.8, and 55.2% male, respectively). At baseline, 102 variables were submitted to the least absolute shrinkage and selection operator (Lasso) regression algorithm for variable selection. The selected variables were processed by the multivariable Cox proportional hazards regression modeling combined with univariate analysis and stepwise regression. The model was evaluated by the concordance index (C-index) and calibration plot. Finally, the nomogram was provided to visualize the results. The improvement in the regression model was calculated by the net reclassification index (NRI) (with tenfold cross-validation and 200 bootstraps).Results: Among the selected 2,980 patients, 1,696 (56.9%) were readmitted within 180 days, and 1,502 (50.4%) were men. A nomogram was established by the results of Lasso regression, univariate analysis, stepwise regression and multivariate Cox regression, as well as variables with clinical significance. The values of the C-index were 0.75 [95% confidence interval (CI): 0.72–0.79], 0.75 [95% CI: 0.69–0.81], and 0.73 [95% CI: 0.64–0.83] for the development, internal validation, and external validation datasets, respectively. Calibration plots were provided for both the internal and external validation sets. Five variables including history of acute heart failure, emergency department visit, age, blood urea nitrogen level, and beta blocker usage were considered in the final prediction model. When adding variables involving hospital discharge way, alcohol taken and left bundle branch block, the calculated values of NRI demonstrated no significant improvements.Conclusions: A nomogram for the prediction of 180-day readmission of patients with CHF was developed and validated based on five variables. The proposed methodology can improve the accurate prediction of patient readmission and have the wide applications for CHF.